



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	396773	Oxyguard
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Biomedica Nutraceuticals Pty Ltd	
<b>Postal Address</b>	PO Box 7052, ALEXANDRIA, NSW, 2015 Australia	
<b>ARTG Start Date</b>	30/09/2022	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Oxyguard

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	10/02/2023
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

Antioxidant/Reduce free radicals formed in the body  
Helps reduce/decrease free radical damage to body cells  
Maintain/support collagen formation  
Maintain/support general health and wellbeing  
Maintain/support gum health  
Maintain/support connective tissue health  
Aid/assist/helps connective tissue production/formation  
Maintain/support bone health  
Aids/assists healthy bone development/growth/building  
Helps maintain/supports healthy joint cartilage growth/development/production  
Helps maintain/support joint cartilage health  
Helps maintain/support healthy cholesterol  
Maintain/support cardiovascular system health  
Maintain/support healthy cardiovascular system function  
Maintain/support blood capillary health  
Maintain/support blood vessel health  
Maintain/support immune system health  
Maintain/support healthy immune system function  
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency  
Maintain/support wound healing  
Maintain/support skin repair/healing/regeneration

### Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must not imply or refer to serious cardiovascular conditions.

Public Summary



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.

Product presentation must not imply or refer to any form of arthritis or osteoarthritis unless qualified as mild.

Product presentation must not imply or refer to serious immunological diseases.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to lowering or raising blood cholesterol levels from outside of the normal healthy range

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

No Specific Indications included on Record

#### Warnings

The recommended dose of this medicine provides small amounts of caffeine

This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.

#### Additional Product information

#### Pack Size/Poison information

##### Pack Size

##### Poison Schedule

#### Components

##### 1 . Formulation 1

**Dosage Form** Capsule, hard

**Route of Administration** Oral

##### Visual Identification

##### Active Ingredients

<b>ascorbic acid</b>	<b>120 mg</b>
<b>betacarotene</b>	<b>3 mg</b>
<b>Camellia sinensis leaf Extract dry concentrate standardised</b>	<b>50 mg</b>
Equivalent: Camellia sinensis (Dry)	1.5 g
<b>Curcuma longa rhizome Extract dry concentrate</b>	<b>30 mg</b>
Equivalent: Curcuma longa (Dry)	300 mg
<b>cysteine hydrochloride monohydrate</b>	<b>50 mg</b>
Equivalent: cysteine	34.5 mg
<b>d-alpha-tocopheryl acid succinate</b>	<b>82.64 mg</b>
Equivalent: d-alpha-tocopherol	100 IU
<b>Ginkgo biloba leaf Extract dry concentrate</b>	<b>6 mg</b>
Equivalent: Ginkgo biloba (Dry)	300 mg
<b>glutamine</b>	<b>50 mg</b>
<b>glycine</b>	<b>50 mg</b>
<b>mixed (low-alpha type) tocopherols concentrate</b>	<b>5.001 mg</b>
<b>Reynoutria japonica root Extract dry concentrate standardised</b>	<b>50 mg</b>
Equivalent: Reynoutria japonica (Dry)	5 g
<b>rutoside</b>	<b>100 mg</b>
<b>selenomethionine</b>	<b>125 microgram</b>
Equivalent: selenium	50 microgram
<b>Silybum marianum fruit Extract dry concentrate</b>	<b>11.43 mg</b>
Equivalent: Silybum marianum (Dry)	800 mg
<b>Vaccinium myrtillus fruit Extract dry concentrate</b>	<b>1 mg</b>
Equivalent: Vaccinium myrtillus (Fresh)	100 mg
<b>Vitis vinifera seed Extract dry concentrate</b>	<b>4.167 mg</b>

# Public Summary



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration

Equivalent: Vitis vinifera (Dry)	500 mg
<b>zinc citrate dihydrate</b>	<b>15.58 mg</b>
Equivalent: zinc	5 mg

Other Ingredients (Excipients)

Acacia  
colloidal anhydrous silica  
hypromellose  
maltodextrin  
microcrystalline cellulose  
Pea Starch  
potable water  
purified water  
silicon dioxide  
sodium alginate  
sodium starch glycollate  
Soya Oil  
stearic acid

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary